Drugs / TNG462
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06922591 | May 2025 → Jun 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Tango Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06188702 | Apr 2024 → May 2027 expected | — | Servier Bio-Innovation LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05732831 | May 2023 → May 2026 overdue | — | Tango Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNG462 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06188702 ↗ |
| Action | Inhibit | “selective PRMT5 inhibitor” NCT05732831 ↗ |
| Route | Oral | “will be administered orally” NCT05732831 ↗ |
| Target | PRMT5 | “selective PRMT5 inhibitor” NCT05732831 ↗ |